Hepatitis B virus therapy: What&rsquo;s the future holding for us?

doi:10.3748/wjg.v21.i44.12558

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 44

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (31674)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

1484

WORD

756

HTML

13330

Figures (1-1)

332

Tables (1-5)

220

Sum=16122

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

11668

Download

1461

Sum=13129

Publishing Process of This Article

Item

Count

Browse

974

Download

1449

Sum=2423

Nov 28, 2015 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (36)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Nov 28, 2015; 21(44): 12558-12575
Published online Nov 28, 2015. doi: 10.3748/wjg.v21.i44.12558

Table 3 Immunomodulators in pipeline for hepatitis B virus treatment

Immune enhancer	Function	Developer	Phase
CYT-107	Recombinant IL-7	Cytheris SA, France	Phase II
TG-1050	Adenovirus based targeted immunotherapy	Transgene SA, France	Pre-clinical
GS-9620	TLR-7 agonist	Gilead Sciences, United States	Phase II
GC1102	Monoclonal antibodyRecombinant HBIg	Green Cross Corporation, Japan	Phase II
CYT-003	TLR-9 agonist	Tekmira Pharmaceuticals Corporation, Canada	Pre-clinical (Phase II for Asthma)
SB 9200	RIG-I and NOD2 activator	Spring Bank Pharmaceuticals, United States	Phase II

HBV: Hepatitis B virus; HBIg: Hepatitis B Immunoglobulin; TLR: Toll-like receptor; RIG-I: Retinoic acid-inducible gene I; NOD2: Nucleotide-binding oligomerization domain containing 2; IL-7: Interleukin-7.

Citation: Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What’s the future holding for us? World J Gastroenterol 2015; 21(44): 12558-12575
URL: https://www.wjgnet.com/1007-9327/full/v21/i44/12558.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i44.12558